Duloxetine News and Research

RSS
Duloxetine is approved in the United States for the acute and maintenance treatment of major depressive disorder, the acute treatment of generalized anxiety disorder, and the management of diabetic peripheral neuropathic pain and fibromyalgia in adults aged 18 years and older. Duloxetine is not approved for use in pediatric patients.
Merck update on the status of telcagepant clinical development programs

Merck update on the status of telcagepant clinical development programs

Venlafaxine alleviates depressive symptoms

Venlafaxine alleviates depressive symptoms

Lilly resubmits Cymbalta supplemental NDA for chronic pain to FDA

Lilly resubmits Cymbalta supplemental NDA for chronic pain to FDA

New antidepressants might be no more effective than the best existing drugs

New antidepressants might be no more effective than the best existing drugs

Cymbalta (duloxetine HCl) shown to delay new episodes of depression

Cymbalta (duloxetine HCl) shown to delay new episodes of depression

Eli Lilly withdraws application for additional U.S. indication for Cymbalta for chronic pain

Eli Lilly withdraws application for additional U.S. indication for Cymbalta for chronic pain

Cymbalta approved in Europe for generalised anxiety disorder

Cymbalta approved in Europe for generalised anxiety disorder

Cymbalta approved for fibromyalgia

Cymbalta approved for fibromyalgia

Antidepressants might be worthless for treating low back pain

Antidepressants might be worthless for treating low back pain

Duloxetine does not relieve painful physical symptoms in depression

Duloxetine does not relieve painful physical symptoms in depression

FDA approves Cymbalta for maintenance treatment of major depressive disorder

FDA approves Cymbalta for maintenance treatment of major depressive disorder

FDA approves antidepressant Cymbalta (duloxetine HCl) for treatment of generalized anxiety disorder

FDA approves antidepressant Cymbalta (duloxetine HCl) for treatment of generalized anxiety disorder

Duloxetine proven effective for use in men with stress urinary incontinence after radical prostatectomy

Duloxetine proven effective for use in men with stress urinary incontinence after radical prostatectomy

Lilly submits Cymbalta NDA for generalized anxiety disorder

Lilly submits Cymbalta NDA for generalized anxiety disorder

Drug company warns of risk of liver problems with antidepressant

Drug company warns of risk of liver problems with antidepressant

Cymbalta improves cognitive function in elderly patients with depression

Cymbalta improves cognitive function in elderly patients with depression

European approval of Cymbalta/Xeristar for treatment of major depressive episodes

European approval of Cymbalta/Xeristar for treatment of major depressive episodes

Cymbalta significantly reduced pain in more than half of women treated for fibromyalgia, with and without major depression

Cymbalta significantly reduced pain in more than half of women treated for fibromyalgia, with and without major depression

European positive for Cymbalta and Xeristar

European positive for Cymbalta and Xeristar

Yentreve available in Europe for treatment of stress urinary incontinence

Yentreve available in Europe for treatment of stress urinary incontinence